Ghost-authors, improvement article comunication, and medical publications;Autores-fantasma, mejora en la comunicación de artículos y publicaciones médicas

Neurologia

Volumn 26, Issue 5, 2011, Pages 257-261

  Matias Guiu J ^a   Garcia Ramos R ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Authors; Editors; Ghost author; Ghost writers; Medical journals; Medical writers; Pharmaceutical industry

Indexed keywords

ARTICLE; AUTHOR; DRUG INDUSTRY; MEDICAL LITERATURE; PUBLICATION; SCIENTIFIC LITERATURE; WRITING;

AUTHORSHIP; PUBLISHING; WRITING;

EID: 79956199431     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2010.12.001     Document Type: Article

References (61)

1. Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold "HRT" PLoS Med. 2010;9:e1000335. doi:10.1371/journal.pmed.1000335.
2. Laine C., Mulrow C.D. Exorcising ghosts and unwelcome guests. Ann Intern Med. 2005, 143:611-612.
3. Editor. Ghost with a chance in publishing undergrowth. Lancet. 1993;342:1498-9.
4. Moffatt B., Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med. 2007, 50:18-31.
5. Ross J.S., Hill K.P., Egilman D.S., Krumholz H.M. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008, 299:1800-1812.
6. DeAngelis C.D., Fontanarosa P.B. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA. 2008, 299:1833-1835.
7. Lagnado M. Increasing the trust in scientific authorship. Br J Psychiatry. 2003, 183:3-4.
8. Bevan J.C. Ethical behaviour of authors in biomedical journalism. Ann R Coll Physicians Surg Can. 2002, 35:81-85.
9. Bodenheimer T. Uneasy alliance - clinical investigators and the pharmaceutical industry. N Engl J Med. 2000, 342:1539-1544.
10. Schulman K.A., Seils D.M., Timbie J.W., Sugarman J., Dame L.A., Weinfurt K.P., et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002, 347:1335-1341.
11. Halperin S.A., Scheifele D., Duval B., Ward B. Conforming to ICMJE principles. CMAJ. 2005, 173:1358-1359.
12. Fugh-Berman A. The corporate coauthor. J Gen Intern Med. 2005, 20:546-548.
13. S Matias-Guiu F J., S Garcia-Ramos F R. Sesgos en la edición de las publicaciones científicas. Neurologia 2011. doi:10.1016/j.nrl.2010.11.001.
14. Daskalopoulou S.S., Mikhailidis D.P. The involvement of professional medical writers in medical publications. Curr Med Res Opin. 2005, 21:307-310.
15. Iniesta I. Neurology and literature. Neurologia. 2010, 25:507-514.
16. CBE. Who is an author? Science Editor. 2000; 23:111.
17. Angell M. The pharmaceutical industry - to whom is it accountable?. N Engl J Med. 2000, 342:1902-1904.
18. Healy D., Cattell D. Interface between authorship, industry and science in the domain of therapeutics. Br J Psych. 2003, 183:22.
19. Djulbegovic B., Lacevic M., Cantor A., Fields K.K., Bennett C.L., Adams J.R., et al. The uncertainty principle and industry-sponsored research. Lancet. 2000, 356:635-638.
20. Ngai S., Gold J.L., Gill S.S., Rochon P.A. Haunted manuscripts: ghost authorship in the medical literature. Account Res. 2005, 12:103-114.
21. Fugh-Berman A., Dodgson S. The ethics of publication planning in the pharmaceutical industry. Open Medicine. 2008, 2:33-36.
22. Fugh-Berman A., Melnick D. Off-label promotion, on-target sales. PLoS Med. 2008, 5:210.
23. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?. PLoS Med. 2007, 4:286.
24. Jacobs A. Transparency and trust: in defence of medical writers. BMJ. 2004, 329:1345.
25. Hamilton C.W. Don't get spooked! How to collaborate with a professional medical communicator (and avoid ghostwriting). Arch Immunol Ther Exp (Warsz). 2010, 58:255-261.
26. Jacobs A., Carpenter J., Donnelly J., Klapproth J.F., Gertel A., Hall G., et al. The involvement of professional medical writers in medical publications: results of a Delphi study. Curr Med Res Opin. 2005, 21:311-316.
27. Shashok K. Content and communication: how can peer review provide helpful feedback about the writing?. BMC Med Res Methodol. 2008, 31:3.
28. Shashok K. Responsabilidades compartidas en la revisión de los originales por expertos. Rev Neurol. 1997, 148:1946-1950.
29. Matías-Guiu J., Moral E., García-Ramos R., Martínez-Vila E. The profile of evaluators of a medical publication in relation to the response. Neurologia. 2010, 25:530-535.
30. Matias-Guiu J., García-Ramos R. El proceso de mejora y decisión de un artículo. Neurologia. 2009, 24:353-358.
31. Shashok K. Author's editors: facilitators of science information transfer. Learned Publishing. 2001, 14:113-121.
32. Hartley J., Branthwaite A., Ganier F., Heurley L. Lost in translation: Contributions of editors to the meanings of text. J Information Sci. 2007, 33:551-565.
33. Horton R. The rhetoric of research. BMJ. 1995, 310:985-987.
34. Freeman P., Robbins A. The publishing gap between rich and poor: the focus of Author aid. J Public Health Policy. 2006, 27:196-203.
35. Gøtzsche P.C., Kassirer J.P., Woolley K.L., Wager E., Jacobs A., Gertel A., et al. What should be done to tackle ghostwriting in the medical literature?. PLoS Med. 2009, 6:23.
36. Norris R., Bowman A., Fagan J.M., Gallagher E.R., Geraci A.B., Gertel A., et al. International Society for Medical Publication Professionals (ISMPP) position statement: the role of the professional medical writer. Curr Med Res Opin. 2007, 23:1837-1840.
37. Matias-Guiu J., García-Ramos R. Fraude y conductas inapropiadas en las publicaciones científicas. Neurologia. 2010, 25:1-4.
38. Ray J.G. Judging the judges: the role of journal editors. QJM. 2002, 95:769-774.
39. Shahok K., Jacobs A. Who's watching whose ethics? Slanted reportig of the medical writer's role in the Neuropsychopharmacology- Ciberonics Case 1. The Write Stuff. 2007, 16:1-3.
40. Jacobs A., Wager E. European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin. 2005, 21:317-322.
41. Wager E., Field E.A., Grossman L. Good publication practice for pharmaceutical companies. Curr Med Res Opin. 2003, 19:149-154.
42. Fugh-Berman A., Scialli A.R. Gynecologists and estrogen: an affair of the heart. Perspect Biol Med. 2006, 49:115-130.
43. Dowsett S.A., Van Campen L.E., Bednar L.A. Developing good scientific publishing practices: one pharmaceutical company's perspective. Curr Med Res Opin. 2010, 26:1249-1254.
44. Gøtzsche P.C., Hróbjartsson A., Johansen H.K., Haahr M.T., Altman D.G., Chan A.W. Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007, 4:e535.
45. Wager E. Authors, ghosts, damned lies, and statisticians. PLoS Med. 2007, 4:e34.
46. Lacasse JR, Leo J. Ghostwriting at elite academic medical centers in the United States. Plos Med. 2010;7:e1000230. doi:10.1371/journal.pmed.1000230.
47. Górski A., Letkiewicz S. "Medical writing" and ghostwriting as ethical challenges in medical communication. Transplant Proc. 2010, 42:3335-3337.
48. McHenry L., Jureidini J. Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study. Accountability Res. 2008, 15:152-167.
49. Landefeld C.S., Steinman M.A. The Neurontin legacy - marketing through misinformation and manipulation. NEJM. 2009, 360:103-105.
50. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. Soc Stud Sci. 2009, 39:171-198.
51. Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. Disponible en: www.icmje.org.
52. Peh W.C., Ng K.H. Authorship and acknowledgements. Singapore Med J. 2009, 50:563-565.
53. Matías-Guiu J., García-Ramos R. Autor y autoría en las publicaciones médicas. Neurología. 2009, 24:1-6.
54. Schultz H.Y., Blalock E. Transparency is the key to the relationship between biomedical journals and medical writers. Invest Dermatol. 2007, 127:735-737.
55. Garrow J., Butterfield M., Marshall J., Williamson A. The reported training and experience of editors in chief of specialist clinical medical journals. JAMA. 1998, 280:286-287.
56. Matías-Guiu J., García-Ramos R. Independencia editorial. Neurologia. 2010, 25:339-342.
57. Matías-Guiu J., García-Ramos R. El factor de impacto y las decisiones editoriales. Neurología. 2008, 23:342-348.
58. Angell M. Publish or perish: a proposal. Ann Intern Med. 1986, 104:261-262.
59. Urbano C. El análisis de citas de trabajos de investigadores como método para el estudio del uso de información en bibliotecas. An Docum. 2001, 4:243-266.
60. Vivas N., Bosch F. Análisis bibliométrico de la actividad investigadora de la industria farmacéutica española. Farm Clin. 1991, 8:768-776.
61. Mowatt G., Shirran L., Grimshaw J.M., Rennie D., Flanagin A., Yank V., et al. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA. 2002, 287:2769-2771.